Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats
| Autor: | Kruse Cornelis G, A. van Loevezijn, Sven Akkerman, Jennifer Venhorst, P. Houba, Olga A.H. Reneerkens, L. de Groote, Jos Prickaerts, N.M.W.J. de Bruin |
|---|---|
| Přispěvatelé: | Psychiatrie & Neuropsychologie, RS: MHeNs School for Mental Health and Neuroscience |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.drug_class Cognitive Neuroscience Scopolamine Experimental and Cognitive Psychology Pharmacology Guanidines Developmental psychology Behavioral Neuroscience chemistry.chemical_compound Piperidines Oral administration mental disorders medicine Animals Donepezil Object location task (OLT) Memory disorder Rats Wistar Maze Learning Nootropic Agents Memory Disorders Sulfonamides business.industry Antagonist Muscarinic antagonist Recognition Psychology 5-HT6 antagonist medicine.disease Acetylcholinesterase Rats Wistar rats carbohydrates (lipids) GSK-742457 Acetylcholinesterase inhibitor chemistry Indans Exploratory Behavior 5-HT6 receptor Object recognition task (ORT) Cholinesterase Inhibitors Serotonin Antagonists business Neuroscience medicine.drug |
| Zdroj: | Neurobiology of Learning and Memory, 96(2), 392-402. Elsevier Science |
| ISSN: | 1074-7427 |
| Popis: | The 5-hydroxytryptamine(6) (5-HT(6)) receptor has been suggested to play an important role in the regulation of memory and cognition. In the present study, our aim was to investigate whether the novel, selective 5-HT(6) antagonists compound (CMP) X and CMP Y and the reference 5-HT(6) antagonist GSK-742457 could ameliorate impairments in episodic memory in 3-months-old male Wistar rats. The acetylcholinesterase inhibitor (AChEI) donepezil (Aricept®, approved for symptomatic treatment of Alzheimer's disease, AD) was used as a positive reference compound. First, effects of the 5-HT(6) antagonists CMP X, CMP Y and GSK-742457 were investigated on object recognition task (ORT) performance in rats treated with the muscarinic antagonist scopolamine (0.1mg/kg, administered intraperitoneally, i.p., 30 min before trial 1). Second, effects of the combination of suboptimal doses of 5-HT(6) antagonists CMP X and CMP Y with the AChEI donepezil were studied, to determine whether the 5-HT(6) antagonists show additive synergism with donepezil in the ORT. Finally, effects of CMP Y, GSK-742457 and donepezil were investigated on object location task (OLT) performance in rats treated with scopolamine. Donepezil (1mg/kg, oral administration, p.o.), GSK-742457 (3mg/kg, i.p.), CMP X (3mg/kg, i.p.) and CMP Y (30 mg/kg, p.o.), all ameliorated the scopolamine-induced deficits in object recognition. In the ORT, we have found that combined administration of subthreshold doses of CMP X (1mg/kg, i.p.) and CMP Y (10mg/kg, p.o.) with the AChEI donepezil (0.1mg/kg, p.o.), enhanced memory performance in Wistar rats with deficits induced by scopolamine. Donepezil (0.1mg/kg, p.o.) alone had no discernable effects on performance. This suggests additive synergistic effects of the 5-HT(6) antagonists (CMP X and CMP Y) with donepezil on cognitive impairment. Finally, donepezil (1mg/kg, p.o.), GSK-742457 (10mg/kg, p.o.) and CMP Y (30 mg/kg, p.o.) also reduced scopolamine-induced deficits in the OLT. In conclusion, the 5-HT(6) antagonists were found to clearly improve episodic memory deficits induced by scopolamine. In addition, co-administration of the 5-HT(6) receptor antagonists CMP X and CMP Y with the AChEI donepezil to cognitively impaired rats also resulted in potentially additive enhancing effects on cognition. This suggests that these compounds could have potential as monotherapy, but also as adjunctive therapy in patients with AD treated with common treatments such as donepezil. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect